Applied Therapeutics (APLT)

Overall impact
C (52)

Commentary

Applied Therapeutics is an average overall performer. With a 'C' rating of 52.4 for overall impact (46th percentile compared to all companies), Applied Therapeutics ranks 512th out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 508 others, and ahead of Jazz Pharmaceuticals, Citius Pharmaceuticals, Mereo BioPharma and 70 others. On top material causes for Applied Therapeutics's industry (Pharmaceuticals & Biotech), Applied Therapeutics performs well in Child and Maternal Health (87.1 score), Disease Eradication (96.4) and Child and Maternal Health (86.5) and performs poorly in Decent, Safe Work Opportunities (30.4 score), Disaster Readiness and Effective Aid (21.5), Sustainable Use of Natural Resources (29.9) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause APLT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
28
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
APLT
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for Applied Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.